title: Use of the PRIME-MD Patient Health Questionnaire for estimating the prevalence of psychiatric disorders in French primary care: comparison with family practitioner estimates and relationship to psychotropic medication use.
abstract: OBJECTIVE
  The objectives of this study were to establish provisional psychiatric diagnoses using the Primary Care Evaluation of Mental Disorders Patient Health Questionnaire (PHQ) and to describe family practitioner (FP) case recognition, survey-day prescription of anxiolytic and antidepressant medications and overall consumption rates (medication use).
  
  
  METHODS
  Between October 2003 and April 2004, 1151 consecutive patients (> or = 18 years old) of 46 FPs practicing in and around the city of Montpellier, France, completed the PHQ. During the consultation, FPs rated the severity of any psychiatric disorder.
  
  
  RESULTS
  PHQ prevalence rates (FP case recognition percentages are given in parentheses) were as follows: 10.9% (36%) for probable alcohol abuse/dependence; 11.3% (40%) for somatoform disorder; 9.1% (75%) for major depression; 7.4% (42%) for other depressive disorders; 7.5% (69%) for panic disorder; and 6% (69%) for other anxiety disorders. The prescription rate for all study patients was 11.3%, ranging from 6.2% for those without a PHQ disorder to 30.3% for those with a PHQ diagnosis of anxiety or depression to 48.2% for FP-recognized cases. The estimated survey-day consumption rate for these medications was 19.4%.
  
  
  CONCLUSIONS
  High consumption of anxiolytic and antidepressant medications in France is confirmed but not explained either by higher prevalence rates of psychiatric disorders as compared with other locations or by unusually high survey-day prescription rates. A possible explanation would be the organization of the French health care system, which has multiple sources for obtaining medication.
authors.affiliation: Institut National de la Santé et de la Recherche Médicale (INSERM), U888, Hôpital La Colombière, Pavillon 42, 39 av. Charles Flahault, BP 34493, 34093 Montpellier Cedex 5, France. norton@montp.inserm.fr
authors.forename: Joanna
authors.initials: J
authors.lastname: Norton
authors.forename: Guilhem
authors.initials: G
authors.lastname: De Roquefeuil
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Boulenger
authors.forename: Karen
authors.initials: K
authors.lastname: Ritchie
authors.forename: Anthony
authors.initials: A
authors.lastname: Mann
authors.forename: Andre
authors.initials: A
authors.lastname: Tylee
mesh_terms: D000328:Adult; D000368:Aged; D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use; D005194:Family Practice; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology*; D008875:Middle Aged; D011320:Primary Health Care; D011619:Psychotropic Drugs / Q000627:therapeutic use*; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires
chemical_list: D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D011619:Psychotropic Drugs